Nutriband Inc. (NASDAQ: NTRB) and Its AVERSA™ Abuse-Deterrent Technology: Key FAQs
Summary
What is Nutriband Inc.’s AVERSA™ platform?
The AVERSA™ platform is Nutriband’s proprietary transdermal system designed to reduce abuse, diversion, and accidental exposure of potent drugs like fentanyl, with patents granted in 46 countries.
Why is the AVERSA™ Fentanyl patch significant?
The AVERSA™ Fentanyl patch targets a $80M–$200M U.S. sales opportunity as the first abuse-deterrent opioid patch, addressing a critical need for safer drug delivery options.
How does Nutriband protect its AVERSA™ technology?
Nutriband strengthens its intellectual property through U.S. trademarks and international patents, including a recent trademark for ‘Nutriband™’ and a patent in Macao, totaling 46 countries with protection.
What strategic partnership has Nutriband entered into?
Nutriband has formed a strategic sports partnership with Charlotte FC to enhance brand visibility and community presence.
Where can investors find the latest news about Nutriband?
Investors can access the latest news and updates about Nutriband in the company’s newsroom at https://ibn.fm/NTRB.
What is the significance of Nutriband’s new U.S. trademark?
The new U.S. trademark for ‘Nutriband™’ covers pharmaceutical and product R&D, further solidifying the company’s brand and market position in abuse-deterrent drug delivery.
How does BioMedWire contribute to Nutriband’s communication strategy?
BioMedWire provides Nutriband with a specialized communications platform to reach a wide audience, including investors and the general public, through news distribution and social media.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119487